Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Biopharmaceutics explore the interrelationship of the physical/chemical properties of the drug, the dosage form (drug product) in which the drug is given, and the route of administration on the rate and extent of systemic drug absorption and the use of this information to optimise the therapeutic efficacy of the drug products. The process of movement of drug from its site of administration to the systemic circulation is called as absorption. The concentration of drug in plasma and hence the onset of action, and the intensity and duration of response depend upon the bioavailability of drug from its dosage form. Bioavailability is defined as the rate and extent (amount) of drug absorption. Any alteration in the drug’s bioavailability is reflected in its pharmacological effects. Other processes that play a role in the therapeutic activity of a drug are distribution and elimination.


  • Track 1-1 Pharmacokinetics of drugs
  • Track 1-2Pharmacodynamics of drugs
  • Track 1-3Potency of drug products
  • Track 1-4Applied biopharmaceutics

Drug design is an inventive process of finding new medications of a biological target which frequently but not necessarily relies on computer modelling techniques use of high throughput screening techniques to analyse  a new compounds, both by synthetic and natural, as novel drugs. Regrettably, this approach has yielded very little achievement in the field of anti-infective drug discovery. The identification of both molecular targets that are essential for the survival of the pathogen, and compounds that are active on intact cells, is a challenging task. Even more formidable, however, is the fulfilment for appropriate potency levels and suitable pharmacokinetics, in order to achieve efficacy in small animal disease models.


  • Track 2-1Pharmacogenetics in Drug Discovery and Development
  • Track 2-2Synthesis and Development Techniques in Drug Discover
  • Track 2-3Innovative Strategies to Develop Drug Discovery
  • Track 2-4Latest Development In Drug Discovery
  • Track 2-5Challenges Faced In Drug Discovery
  • Track 2-6Pharmacogenomics Drugs
  • Track 2-7Biological Products Used In Drug Discovery
  • Track 2-8Human Genome Project
  • Track 2-9Cell based Therapies

The assessment of BA/BE of different drug products is based on the fundamental assumption that two products are equivalent when the rate and extent of absorption of the test drug does not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses. Should the rate of absorption actually differ between products, it would have to be intentional and reflected in the proposed product label and be clearly demonstrated that it is not essential in the attainment of effective body drug concentrations on chronic use or has been shown to be medically insignificant for the drug. In practice, equivalence is indicated when key pharmacokinetic parameters used to establish rate and extent of the test, and reference products fall within a present confidence interval. The FDA declares a drug product to be therapeutically equivalent to the innovator product if it is pharmaceutically equivalent, i.e., same active ingredient, dosage form, strength and route of administration, and bioequivalent. Products that are therapeutically equivalent can be used interchangeably. Thus, BE studies are construed to be considered surrogates for comparative clinical trials for the assessment of therapeutic equivalence in safety and efficacy between two drug products.


  • Track 3-1Drug-release studies
  • Track 3-2Drug Absorption and Distribution
  • Track 3-3Bioequivalence Protocols: In vitro-In vivo correlation
  • Track 3-4Dissolution Studies
  • Track 3-5Bio accessibility Factor
  • Track 3-6 BA/BE study for orally inhaled drug products

Clinical Trials is a multidisciplinary program with broad participation with members from around the globe focused on learning about clinical research and its advances. This is your best opportunity to reach the largest assemblage of participants from Clinical Trials community that is from academia, clinical research entities, medical groups, related associations, societies and also from government agencies, pharmaceutical, biomedical and medical device industries. Clinical Trials will discuss various disciplines involved in the pre-clinical research, conduct of clinical trials; it will educate health care researchers about design, operation, organizing, research computing, regulatory aspects and reporting of clinical trials. It promotes better understanding by the general public about the importance of clinical trials in prevention, diagnosis and treatment of disease.


  • Track 4-1Bioassay and its types
  • Track 4-2Preclinical & Clinical Testing
  • Track 4-3Phases of Clinical Research
  • Track 4-4Clinical trial protocol
  • Track 4-5Clinical trial management system
  • Track 4-6Clinical Pharmacology & Toxicology
  • Track 4-7Dose & Therapeutic response
  • Track 4-8Dosage form and route of administration

Regulatory Science is the science of advanced standards equipment, and paths to assess the safety, Drug toxicity and quality, potency of all FDA-regulated products. An access to lengthen the programs in regulatory science that leverages what has been well-educated in the development of training programs for translational scientists, and this model for regulatory science program development is being refined and adopted by all of the institutions that are part of the CTSA network. The target audience for such a program is broad, noted that it is necessary to break out of the mind-set that regulatory science resides totally with FDA and that the field's purpose is to create a workforce that will function within the FDA. Regulatory science is a collaborative effort that goes beyond FDA. Critical needs for a regulatory science training program understand research and scientific methodology, toxicology, therapeutics, and pharmacology that underpin the regulatory process. The importance of intellectual property law is well established at all levels-statutory, administrative and judicial. It lays down minimum standards for protection and enforcement in member countries which are required to promote effective and adequate protection of intellectual property rights with a view to reducing distortions and impediments to international trade.

The Agreement provides norms and standards in respect of following areas of intellectual properties are Patents, Trademarks, copyrights, Geographical indications, Industrial designs.


  • Track 5-1Drug Regulations and Organizations
  • Track 5-2Intellectual Property Law for Generics and Innovator Rights
  • Track 5-3Regulatory Approvals for Biopharma drug products
  • Track 5-4Biopharma Regulatory challenges
  • Track 5-5Safety and Quality Regulation in Labelling
  • Track 5-6Global Pharma Products Registration
  • Track 5-7Overview of drug, biologic and device regulatory pathways

One of the big challenges of medicine today is to deliver drugs specifically to defected cells. Nano particulate drug carriers have the potential to answer to this call, as nanoparticles can cross physiological barriers and access different tissues, and also be provided in a targetable form aimed at enhancing cell specificity of the carrier. Recent developments within material science and strong collaborative efforts crossing disciplinary borders have highlighted the potential of mesoporous silica nanoparticles (MSNs) for such targeted drug delivery. Here we outline recent advances which in this sense push MSNs to the forefront of drug delivery development. Relatively straightforward inside-out tuning of the vehicles, high flexibility, and potential for sophisticated release mechanisms make these nanostructures promising candidates for targeted drug delivery such as ‘smart’ cancer therapies. Moreover, due to the large surface area and the controllable surface functionality of MSNs, they can be controllably loaded with large amounts of drugs and coupled to homing molecules to facilitate active targeting, simultaneously carrying traceable (fluorescent or magnetically active) modalities, also making them highly interesting.


  • Track 6-1Patient advocacy
  • Track 6-2Evolution of generic drugs
  • Track 6-3Role of Biogenomic in emergency medicine
  • Track 6-4Advanced drug kinetics
  • Track 6-5Recent technology in Biopharmaceuticals
  • Track 6-6Carbon nano tubes
  • Track 6-7Gold nano particles
  • Track 6-8Quantum dots

Pharmaceutical sciences combine a broad range of scientific disciplines that are involved with the design, action, delivery, disposition and use of drugs. This field draws on many areas of the basic and applied sciences such as chemistry, biology, epidemiology, statistics, chemo metrics, mathematics, physics and chemical engineering and applies their principles to the study of drugs.



  • Track 7-1Preformulation studies
  • Track 7-2Pharmaceutical formulations
  • Track 7-3Pharmaceutical materials
  • Track 7-4Routes of drug delivery
  • Track 7-5Drug Discovery, Design & Development
  • Track 7-6Pharmaceutical Manufacturing and Equipment
  • Track 7-7Pharmaceutical Technology & Development
  • Track 7-8Growth Strategies for Pharmaceutical Industries
  • Track 7-9Pharmaceutical biotechnology

The field of Pharmacovigilance is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. Pharma World 2019 emphasizes on how the importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors. With members from around the world focused on learning about Pharmacovigilance and its advances


  • Track 8-1Drug Safety
  • Track 8-2Adverse Drug Reactions
  • Track 8-3Data Quality Management and Analysis
  • Track 8-4Good Pharmacovigilance Practice
  • Track 8-5Pharmacovigilence Scope and Important
  • Track 8-6Risk Management

Good Manufacturing Practices quality of drugs is essentially the responsibility of manufacturers. GMP Guidelines are means to assure this very quality of drugs. CGMP refers to the Current Good Manufacturing Practice regulations enforced by the US Food and Drug Administration (FDA). CGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities. Adherence to the CGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. GMP is actually good common sense quality management quality assurance GMP production and quality control

  • Track 9-1Regulatory Authority
  • Track 9-2Food and Drug Administration (US FDA)
  • Track 9-3Pharma Audit
  • Track 9-4Current Regulations and Quality Standards

Drug Delivery system attains greater global significance as Drug Delivery System plays a significant role in the future of pharmaceutical research Novel drug delivery system method by which a drug is delivered can have a significant effect on its efficacy. This includes topics like lipid Polymers to enhance drug delivery technology by providing controlled release of therapeutic agents in constant doses over long periods, cyclic dosage, and tuneable release of both hydrophilic and hydrophobic drugs. The major part is to deliver an innovative speech on the latest Targeted drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to other drugs.

The method by which a drug is delivered can have a significant effect on its efficacy. Some drugs have an optimum concentration range within which maximum benefit is derived, and concentrations above or below this range can be toxic or produce no therapeutic benefit at all. On the other hand, the very slow progress in the efficacy of the treatment of severe diseases, has suggested a growing need for a multidisciplinary approach to the delivery of therapeutics to targets in tissues.


  • Track 10-1Control release drug delivery system
  • Track 10-2 Advancements in oral drug delivery
  • Track 10-3Transdermal drug delivery system
  • Track 10-4Targeted drug delivery

Clinical trials are research concentrates that investigate whether a restorative technique, treatment, or gadget is protected and compelling for people. Contemplate indicate which therapeutic methodologies work best for specific ailments or gatherings of individuals. The reason for clinical trials is research, so the reviews take after strict logical models. These measures ensure patients and help deliver dependable review comes about. Clinical trials are one of the last phases of a long and watchful research prepare.

Clinical research concentrates to explore whether a remedial system, treatment, or device is ensured and effective for individuals. Consider show which therapeutic strategies work best for particular afflictions or gatherings of people


  • Track 11-1Pre-Clinical trials
  • Track 11-2Clinical Trials on Various Disorders
  • Track 11-3Diversity in Industrial Clinical Trials and Clinical Research
  • Track 11-4Clinical Research and Statistics
  • Track 11-5Case Report in Clinical Trials
  • Track 11-6Recent Updates on Clinical Trials
  • Track 11-7Clinical Molecular Genetics
  • Track 11-8Clinical Drug Development and Therapeutics
  • Track 11-9Clinical Research and Methodology

Pharmaceutical Analysis is a process or a sequence of processes to identify and/or quantify a substance or drug, the components of a pharmaceutical solution or mixture or the determination of the structures of chemical compounds used in the formulation of pharmaceutical product. Analytical techniques mainly used for the separation of the components from the mixture and for the determination of the structure of the compounds. For the administration of drugs various chemical and instrumental methods were developed at regular intervals which are involved in the estimation of drugs. Analytical instrumentation and methods play an important role. Different analytical techniques and electrochemical methods like Chromatographic techniques, HPLC, Gas chromatography.  From the stages of drug development to marketing and post marketing, analytical techniques play a great role in understanding the physical and chemical stability of the drug, identification of impurities Analytical techniques are mainly used to determine the safety and efficacy of the drug.

The worldwide income of the statistical surveying industry surpassed 40 billion U.S. dollars in 2013, rising year-on-year since it encountered a slight plunge in 2009 amid the Great Recession. In 2013, Europe produced the biggest offer of statistical surveying income at 40 percent, or 16 billion U.S. dollars, nearly taken after by North America with 39 percent. Notwithstanding contributing the most income that year, Europe additionally observed the biggest decrease in income over the earlier year, falling by 1.4 per cent.


  • Track 12-1Novel Approaches to Analytical and Bioanalytical Methods
  • Track 12-2Market Analysis for Pharmaceutical products
  • Track 12-3Analytical Techniques for the development of new drugs
  • Track 12-4Chromatography and Separation Techniques
  • Track 12-5Drug Evaluation Methods for Pharmaceuticals
  • Track 12-6Analytical Method Development and Validation
  • Track 12-7Modern Pharmaceutical Analysis
  • Track 12-8Nuclear Magnetic Resonance

Pharmacodynamics is the significance that drugs have on the main part; while pharmacokinetics is the study of the way in which drugs move through the body during absorption, distribution, metabolism and excretion. Pharmacokinetics influences decisions over the route of administration. For drugs to produce their effects they must interact with the body. This can ensue in several behaviours and depends on the properties of the drug, and will be discussed later in this chapter. Pharmacokinetics influences decisions over the route of administration. The processes that occur after drug admin can be fragmented down into four distinct areas (known as ADME).


  • Track 13-1Solubility of poorly and high soluble drug
  • Track 13-2Recent Biopharmaceutical Innovations
  • Track 13-3PK and PD in New Drug Development
  • Track 13-4 Drug-Drug Interaction

Biosimilars are the generic version of biologicals. A biosimilar is a biologic therapeutic item which is duplicate of a unique item that is produced by an alternate organization. Biosimilars are highly comparable to licensed reference product not accept minor differences in clinically passive components; also there are no clinically needful disparities between the biologicals and the reference product in terms of safety, purity, and potency.

Biologic Drugs are genetically occurred from a living organism, such as a virus, protein, to maintain the body’s natural response to infections and diseases. Biologics target proteins, and cells responsible for the manifestation and damage of rheumatoid arthritis and other types of inflammatory arthritis.

Biologics are reserved for people whose arthritis has not retorted well to disease-modifying anti rheumatic drugs (DMARDs).Biopharmaceutical otherwise called a biologic therapeutic item or biologic, is any restorative item made in, extricated from, or semi orchestrated from organic sources. Not quite the same as synthetically incorporated pharmaceuticals, they incorporate immunizations, blood, or blood segments, allergenic, substantial cells, quality treatments, tissues, recombinant restorative protein, and living cells utilized as a part of cell treatment.

Biologics can be made out of sugars, proteins, or nucleic acids or complex mixes of these substances, or might live cells or tissues. They are confined from normal sources—human, creature, or microorganism. Phrasing encompassing biopharmaceuticals fluctuates amongst gatherings and elements, with various terms alluding to various subsets of therapeutics inside the general biopharmaceutical class.


  • Track 14-1Biosimilar GMP protein analysis
  • Track 14-2Biosimilar LC/MS analysis for discovery, preclinical, and clinical programs
  • Track 14-3Biosimilars Pharmacoeconomic Modelling
  • Track 14-4 Advances in biological products
  • Track 14-5 Generic biological drugs

The Biopharmaceutical Classification System (BCS) is an experimental model that calculates portability and solubility under endorsed guidelines. The main purpose of the system was to aid in the governance of post-approval modifications and generics, providing approvals based solely on in vitro data when applicable. Waivers, dispensation to skip in vivo bioequivalence studies, are reserved for drug products that expedient certain concerns around solubility and permeability and that are also rapidly dissolving. The objective of this work was to advise the biowaivers potential of biopharmaceutical classification system which is known to increase the solubility, dissolution, oral absorption of water insoluble drugs.


A number of techniques can be adapted to develop solubilisation of poor water soluble drug and further to improve its bioavailability. Solubilisation of meagrely soluble drugs is a periodically encountered objection in screening studies of advanced chemical entities as well as in formulation architecture and advancement. Any drug to be absorbed necessary to be existent in the form of an aqueous solution at the site of absorption. ‘Solubility’ is defined as maximum amount of solute that can be dissolved in a given amount of solvent. Quantitatively it is defined as the concentration of the solute in a saturated solution at a certain temperature. In terms of quality, solubility defined as the instinctive communication of two or more substances to produce a homogenous molecular diffusion. A saturated solution is one in which the solute is in stability with the solvent. The solubility of a drug is characterized through several concentration expressions such as parts, percentage, molarity, and molality.



  • Track 15-1BCS biowaivers
  • Track 15-2 Dissolution testing in drug formulation
  • Track 15-3 In vitro diffusion cells for dissolution testing in formulation development
  • Track 15-4In vitro preclinical ADME/BCS testing

Biotherapeutics is illustrated as the process in which different chemical materials are incorporated to form final medicinal substances. The formulation studies associates developing a preparation of drug tolerable for patient. Formulation is the word often used in a way that consists dosage form. Formulation studies examines factors such as solubility, polymorphism, particle size, and pH as all of these can effects bioavailability and hence the reaction of a drug.

Formulations are classified into two types: based on Route of administration and Physical form. Based on route of administration they are classified as Oral, Topical, Rectal, Parenteral, Vaginal, Inhaled, Ophthalmic and Octic.


  • Track 16-1Types: Parenteral, Topical, External
  • Track 16-2Routes of administration: Oral, Rectal, Vaginal, Lingual etc.
  • Track 16-3 Inhalation formulations
  • Track 16-4 Formulation from plant source
  • Track 16-5 Formulation from plant source
  • Track 16-6 Other routes

The overall objective of this research program is to promote novel principles for specific drug delivery and targeting to the active site by using complex in vivo models. An innovatory, cutting edge and multi-disciplinary collaboration using clinical models will accommodate research teams from: pharmaceutical technology, material science, biopharmaceutics   and pharmacokinetics, drug metabolism, toxicology, oncology, gastroenterology, endocrinology, urology and regulatory science.


  • Track 17-1 Recent technology in biopharmaceuticals
  • Track 17-2Patient Assistance
  • Track 17-3 Biomedical computational drug discovery
  • Track 17-4 Novel therapeutics of modern biotechnology
  • Track 17-5Bioinformatics

Protein–protein interactions between membrane-localized receptors and intracellular signalling molecules control neuronal function and theoretically provide a rich source of vastly excluded targets for drug discovery in neuropsychopharmacology. But, unlike the well-defined binding pocket of transporters and receptors, the flat, expansive, and adaptive topology of the protein–protein interface presents a sizeable challenge to the goal of identifying small molecules that result in a gain or loss of function of the protein-protein complex. This is offset by the growing body of evidence to suggest that a few amino acids at the interface (‘hot spot’) contribute to the majority of the binding energy in protein–protein interactions suggesting that modulators with a high degree of specificity could be developed. Furthermore, recent approaches in screening technologies and accessibility to an ever-increasing diversity of small molecules propose that protein–protein interactions are a viable option for drug discovery.



  • Track 18-1 Protein-protein Interactions: Druggability and Chemical Space
  • Track 18-2 Protein targeted using nucleosome binding surface
  • Track 18-3 Peptides binding to modulate gene expression
  • Track 18-4Epigenetic agent

For developing a new medicine it will take nearly 10-15 years and on average and costs an average of $2.6 billion. In discovery procedure comprises the initial stages of research, which are intended to recognize an investigational drug and perform primary tests in the lab. This first stage of the process takes   three to six years. By the end, investigators hope to identify a capable drug aspirant to further study in the lab and in animal models, and then in people. These developments offer great ability, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used along with diagnostics, clinical trial protocols must be improved and increased.


  • Track 19-1Analytical strategies for pharmaceutical products
  • Track 19-2Recent trends in Drug Discovery and Development
  • Track 19-3Pharmacoeconomics and pharma market research
  • Track 19-4Drug Prices and Consumer Value in R&D
  • Track 19-5Stability of drugs
  • Track 19-6Active Pharmaceutical Ingredients

Pharmaceutics encompasses a molecular evaluation of drug metabolism and transport processes and the study of genetic, environmental and disease-related factors that regulate or perturb those processes, as well as the fundamental mathematical relationships between enzyme/transporter function, blood concentration-time profiles and the spectrum of pharmacological effects.

Pharmacotherapeutics manages the helpful uses and impacts of medications. Pharmacists are specialists in pharmacotherapy and are in charge of guaranteeing the protected, suitable, and prudent utilization of pharmaceutical medications. As pharmacotherapy masters, pharmacists have duty regarding direct patient care, regularly working as an individual from a multidisciplinary group, and going about as the essential wellspring of medication related data for other social insurance experts. A pharmacotherapy expert is a person who is spent significant time in managing and endorsing medicine, and requires broad scholarly information in pharmacotherapy.


  • Track 20-1 Pharmacoepidimiology and Pharmacotherapy
  • Track 20-2 Pharmacy Practice and Pharmacoeconomy
  • Track 20-3Advances in Clinical Pharmacy
  • Track 20-4 Research methodology and recent updates on clinical trials
  • Track 20-5 Pharmacoepidimiology and Pharmacotherapy

They are experts in the field of medicines and are not only responsible for the dispensing of prescriptions but also the purchase, manufacture and quality testing of all medicines used in a hospital. Many hospital pharmacists are qualified to prescribe in their own right. Pharmacists work closely with medical and nursing staff to ensure that patients receive the best treatment, advising on the selection, dose and administration route. They also provide help and advice to patients in all aspects of their medicines.

In 2013, there were 287,420 pharmacists and 362,690 pharmacy technicians in the United States. Since 2003, the number of pharmacists in the U.S. has fluctuated year to year, but overall has increased approximately 19% in the last decade. The number of pharmacy technicians steadily increased in the same period, adding over 170,000 workers from 2003-2018.

Industrial pharmacy is a discipline which includes manufacturing, development, marketing and distribution of drug products including quality assurance of these activities. The research topics are focussed on solving current general problems in pharmaceutical industry, such as formulation and characterisation of sticky amorphous drugs, problem-solving for paediatric medicines and miniaturisation of manufacturing processes.


  • Track 21-1Drug Interactions
  • Track 21-2Oncology
  • Track 21-3Clinical studies
  • Track 21-4Supply chain

Pharmaceutical building is a piece of pharmaceutical science.innovation which includes improvement and assembling of items, procedures, and parts in the pharmaceuticals business. The touchy advancement in the pharmaceutical business turned into the main thrust for our new Biopharmaceutical Engineering Program. The branch of biopharmaceuticals is quickly forming into upstream medication definitions and downstream plan handle, by utilizing biopharmaceutical designing standards

  • Track 22-1Biomaterials
  • Track 22-2Medical devices
  • Track 22-3Tissue Biomaterials
  • Track 22-4Pharmaceutical engineering

A drug interaction is a situation in which a substance (usually another drug) affects the activity of a drug when both are administered together. This action can be synergistic (when the drug's effect is increased) or antagonistic (when the drug's effect is decreased) or a new effect can be produced that neither produces on its own. Typically, interactions between drugs come to mind (drug-drug interaction). However, interactions may also exist between drugs and foods (drug-food interactions), as well as drugs and medicinal plants or herbs (drug-plant interactions). People taking antidepressant drugs such as monoamine oxidase inhibitors should not take food containing tyramine as hypertensive crisis may occur (an example of a drug-food interaction). These interactions may occur out of accidental misuse or due to lack of knowledge about the active ingredients involved in the relevant substances.


  • Track 23-1Global pharmaceutical market
  • Track 23-2Technological innovations
  • Track 23-3R&D management
  • Track 23-4Emerging markets
  • Track 23-5Innovations of drug enhancements

Pharmaceutical Packaging can be defined as an economical means of providing presentation, protection, identification information, containment, convenience and compliance for a product during storage, carriage, display and until the product is consumed. Packaging must provide protection against climatic conditions biological, physical and chemical hazards and must be economical. Pharmaceutical marketing is based on product type and geography. The pharmaceutical packaging market is constantly advancing and has experienced annual growth of at least five percent per annum in the past few years as with most other packaged goods, pharmaceuticals need reliable and speedy packaging solutions that deliver a combination of product protection, quality, tamper evidence, patient comfort and security needs.


  • Track 24-1Pharmacoeconomics
  • Track 24-2Properties of packing material
  • Track 24-3Blister packages
  • Track 24-4Shrink seal and bands
  • Track 24-5Strip packages

Pharmaceutical Care is a patient-centred, outcomes oriented pharmacy practice that requires the pharmacist to work in concert with the patient and the patient's other healthcare providers to promote health, to prevent disease, and to assess, monitor, initiate, and modify medication use to assure that drug therapy regimens are safe and effective.

A good health system delivers quality services to all people, when and where they need them. The exact configuration of services varies from country to country, but in all cases requires a robust financing mechanism; a well-trained and adequately paid workforce; reliable information on which to base decisions and policies; well maintained facilities and logistics to deliver quality medicines and technologies.


  • Track 25-1Pharmaceutical Care Management
  • Track 25-2Health Care Management and Providers
  • Track 25-3Medical Billing Softwares
  • Track 25-4Medication Management Services

A Biopharmaceutical is also called as a Biological or Biologic pharmaceutical medication item fabricated from organic sources through extraction. The advancement of a pharmaceutical medication normally takes a normal of 10 – 15 years. Such a large amount of exertion, time and cash, it is exceptionally urgent that the correct advancements and materials are received in the examination, improvement and assembling of the pharmaceutical medications, whole process incorporates pre-disclosure, pre-clinical trials, showcase dispatch to post promoting observing. The wellsprings of medication items incorporate peptides and proteins, including monoclonal antibodies and neutralizer pieces. From 2000 to 2006, biologics represented 33% of all New Active Substances that were pre propelled, and are reflected to the present advancement pipelines of the pharmaceutical business.


  • Track 26-1Sources of Biopharmaceuticals
  • Track 26-2Biotechnology tools and methods
  • Track 26-3Sources of downstream processing
  • Track 26-4Bio-imaging

Biopharmaceutical informatics endeavors to use information technology, sequence-and structure-based bioinformatics analyses, molecular modeling and simulations, and statistical data analyze towards biologic drug development. Development of databases containing the experimental data on biophysical stability, safety along with molecular sequence.


  • Track 27-1Applications of Computation in Biologic Drug Development
  • Track 27-2Physics-based molecular modelling
  • Track 27-3Creation of databases and data mining
  • Track 27-4Protein sequence-structural contexts and degradation reaction mechanisms
  • Track 27-5Pre-clinical immunogenicity risk assessment of biotherapeutics
  • Track 27-6De risk biopharmaceutical development

Pharmaceutical analytic market research deals with the collection, analysis, and interpretation of details and information relating to the market environment of a given pharmaceutical product – in general of a medical drug. The primary objective of pharmaceutical market research is to gain as realistic and objective as possible an impression of the marketing opportunities of a given pharmaceutical product, thus enabling the identification of the chances and risks associated with its development potential as early on as possible.


  • Track 28-1Latest Developments In Biopharma Market Trends
  • Track 28-2Novel Approaches In Biopharmaceuticals
  • Track 28-3Biopharmaceutical Manufacturing Process Development
  • Track 28-4Commercialization & Marketing
  • Track 28-5Tech transfer challenges in biopharmaceutical drugs
  • Track 28-6Scale up essentials for biopharmaceutical drugs

Biotechnology is the utilization of living frameworks and creatures to make items, by any innovative applications to make or adjust items or procedures for particular utilize. Science and innovation have in the past assumed an indispensable part in enhancing general wellbeing. Today the commitment of science to enhance general wellbeing and lessen worldwide wellbeing incongruities is more apropos than any other time in recent memory. However the advantages of current medication still have not achieved a huge number of individuals in creating nations. The developing wellbeing variations between the creating and the created world call for critical activity from established researchers.


  • Track 29-1Food and industrial biotechnology
  • Track 29-2Biomedical engineering
  • Track 29-3Biotech pharma quality issues
  • Track 29-4The role of drug metabolism in biotech therapy
  • Track 29-5Green Technology

Genetics is the study of genes, heredity, and genetic variation in living beings. It is basically considered a field of biology, but it bisect often with many of the life sciences like Pharmaceutical Sciences. The other aspects of this are Genetic engineering, Biomedical Engineering, Genomics Proteomics, Clinical engineering, Tissue engineering, biomedical data engineering etc.

The global genetic engineering market is expected to reach $3,514.08 Million by 2019 from $1,845.25 Million in 2014, growing at a CAGR of 13.75%. Increased RandD expenditure and growth of biotechnology and pharmaceutical industries, increased funding for genomics research, and technological advancements are the primary growth drivers for this market during the forecast period (2014–2019).


Drug design, often referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense, drug design involves the design of molecules that are complementary in shape and charge to the bio molecular target with which they interact and therefore will bind to it. Drug design frequently but not necessarily relies on computer modelling techniques. This type of modelling is sometimes referred to as computer-aided drug design. Finally, drug design that relies on the knowledge of the three-dimensional structure of the bimolecular target is known as structure-based drug design. In addition to small molecules, biopharmaceuticals and especially therapeutic antibodies are an increasingly important class of drugs and computational methods for improving the affinity, selectivity, and stability of this protein-based therapeutics have also been developed.